Prostate Cancer Clinical Trial 2018-065

[LCID Study Number: 2018-065]

A Phase I Trial of Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer (CRPC)

The purpose of this study is to determine what the highest tolerated dose of fractionated (split doses) docetaxel in combination with Ra-223 is when given to subjects, whether the two study drugs can be administered safely and whether it controls the cancer effectively.

Disease/Condition: Prostate Cancer

Department: Hematology and Oncology

Location(s): Lahey Hospital & Medical Center (Burlington)

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-2734

View NCT ID 03737370 on ClinicalTrials.gov
Protocol #: 2018-065
Principal Investigator(s): Brendan J. Connell
Study Coordinator(s): Deborah Gannon
Trial Phase: Sponsor Initiated Study Phase 1